Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report

Tadokoro,Tomoko; Morishita,Asahiro; Oura,Kyoko; Fujita,Koji; Mimura,Shima; Sakamoto,Teppei; Nomura,Takako; Tani,Joji; Yoneyama,Hirohito; Masaki,Tsutomu

doi:10.3892/etm.2018.6207

August-2018 Volume 16 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2018 Volume 16 Issue 2

Full Size Image

Case Report

Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report

Authors:
- Tomoko Tadokoro
- Asahiro Morishita
- Kyoko Oura
- Koji Fujita
- Shima Mimura
- Teppei Sakamoto
- Takako Nomura
- Joji Tani
- Hirohito Yoneyama
- Tsutomu Masaki
View Affiliations / Copyright

Affiliations: Department of Gastroenterology and Neurology, Kagawa University School of Medicine/Graduate School of Medicine, Miki, Kagawa 761‑0793, Japan
Pages: 1026-1028
|
Published online on: May 23, 2018

https://doi.org/10.3892/etm.2018.6207
Expand metrics +

Abstract

The treatment of chronic hepatitis C has radically changed due to the development of direct‑acting antiviral agents (DAAs). Twelve‑week treatment with ledipasvir and sofosbuvir (LDV/SOF), a combination of DAAs, is highly effective in patients with hepatitis C virus (HCV) genotype 1 infection. However, the overall sustained virological response rate 12 weeks after the end of treatment (SVR12) is not 100%. Elbasvir (EBR) combined with grazoprevir (GZR) is the latest approved therapy for patients with genotype 1 or 4 chronic hepatitis C. However, to the best of our knowledge no case reports have described retreatment with GZR/EBR in patients with a history of failed LDV/SOF treatment. The present case report indicated a case in which GZR/EBR was effective for the retreatment of a patient with a history of failed LDV/SOF treatment and chronic hepatitis C. The present study indicated a 55‑year‑old Japanese male with a history of chronic hepatitis C and compensated liver cirrhosis. The patient exhibited the amino acid mutation Y93H in NS5A. Therefore, treatment with LDV/SOF was initiated, which was effective and suppressed the virus during oral administration. However, 4 weeks after treatment, the patient's viral load relapsed and returned to its original level. After the patient provided informed consent, treatment with GZR/EBR was initiated. No problems related to GZR/EBR were observed during treatment and the patient's SVR12 was evaluated at 12 weeks posttreatment. In conclusion, GZR/EBR treatment was useful for treating a relapse of HCV genotype 1b infection in the present case after LDV/SOF treatment, despite liver fibrosis, in the presence of the high‑frequency amino acid mutation Y93H in NS5A. Although it will be necessary to examine a large number of cases, the present findings suggest that GZR/EBR may be a potential treatment option for relapse of HCV genotype 1b infection after LDV/SOF treatment.

View Figures

View References

1	Zopf S, Kremer AE, Neurath MF and Siebler J: Advances in hepatitis C therapy: What is the current state-what come's next? World J Hepatol. 8:139–147. 2016. View Article : Google Scholar : PubMed/NCBI
2	Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, et al: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 370:1889–1898. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, et al: NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 52:845–854. 2017. View Article : Google Scholar : PubMed/NCBI
4	Bell AM, Wagner JL, Barber KE and Stover KR: Elbasvir/grazoprevir: A review of the latest agent in the fight against hepatitis C. Int J Hepatol. 2016:38521262016. View Article : Google Scholar : PubMed/NCBI
5	Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, et al: Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 89:284–290. 2017. View Article : Google Scholar : PubMed/NCBI
6	Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y, et al: Real-world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in hcv genotype 1-infected Japanese patients: Achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3/4A inhibitors. Int J Mol Sci. 18(pii): E9062017. View Article : Google Scholar : PubMed/NCBI
7	Kwon HJ, Xing W, Chan K, Niedziela-Majka A, Brendza KM, Kirschberg T, Kato D, Link JO, Cheng G, Liu X and Sakowicz R: Direct binding of ledipasvir to HCV NS5A: Mechanism of resistance to an HCV antiviral agent. PLoS One. 10:e01228442015. View Article : Google Scholar : PubMed/NCBI
8	Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O'Rear JJ and Harrington PR: Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 152:586–597. 2017. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report

This article is mentioned in:

Abstract

Figure 1

Related Articles